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ABSTRACT
The reported incidence of pancreatic neuroendocrine tumors (PanNETs) has increased, due in large part to
improvements in detection and awareness. However, therapeutic options are limited and a critical need
exists for understanding a more thorough characterization of the molecular pathology underlying this
disease. The Men1 knockout mouse model recapitulates the early stage of human PanNET development
and can serve as a foundation for the development of advanced mouse models that are necessary for
preclinical testing. Menin, the product of the MEN1 gene, has been shown to physically interact with the
KMT2A and KMT2B histone methyltransferases. Both the KMT2A and MEN1 genes are located on
chromosome 11q, which frequently undergoes loss of heterozygosity (LOH) in PanNETs. We report herein
that inactivation of Kmt2a in Men1-deﬁcient mice accelerated pancreatic islet tumorigenesis and
shortened the average life span. Increases in cell proliferation were observed in mouse pancreatic islet
tumors upon inactivation of both Kmt2a and Men1. The Kmt2a/Men1 double knockout mouse model can






Pancreatic neuroendocrine tumors (PanNETs) arise from the
endocrine cells of the pancreas. The World Health Organization
(WHO) guidelines grade these tumors as well-differentiated
neuroendocrine tumors, well-differentiated neuroendocrine
carcinomas and poorly differentiated neuroendocrine carcino-
mas.1 Compared to the more common form of pancreatic can-
cer, adenocarcinoma, which arises in exocrine cells, PanNETs
comprise only 2% to 5% of new pancreatic neoplasms according
to current diagnostic procedures.1,2 However, recent epidemio-
logical studies also support that the overall incidence of Pan-
NETs has increased at a statistically signiﬁcant rate due to
improvements in radiological imaging and clinician aware-
ness.3,4 In addition, the prevalence of PanNETs observed in
autopsy studies has been shown to be as high as 10%,2 suggesting
that there may be a great number of undiagnosed, nonfunctional
PanNETs in the general population.
The current approach for the treatment of PanNETs is
surgical resection and management of hormone hypersecre-
tion if feasible. PanNETs tend to grow at a slower rate and
with an overall better prognosis than exocrine tumors.1 The
5-year survival of PanNETs can be as high as 55% when
the tumors are detected before metastasis and are amenable
to surgical resection. Once the tumor becomes metastatic,
the median overall survival rate is approximately 2 years.5
The molecular mechanisms underlying this malignancy are
poorly understood, and the 5-year survival rate has not sig-
niﬁcantly improved over the past several decades. The FDA
recently approved 2 targeted therapies, sunitinib malate and
everolimus, both of which have only shown a modest bene-
ﬁt to patients with PanNETs.6,7 These shortcomings high-
light the need for a better understanding of the molecular
pathology of this disease and the urgency of appropriate
pre-clinical models to validate potential targets to this type
of cancer.
A number of signaling pathways have been shown to be
involved in the tumorigenesis of pancreatic neuroendocrine
cells such as PI3K signaling, mTOR pathway components and
cell cycle regulators. MEN1 is one of the most commonly
mutated genes in PanNETs, with an up to 36% mutation fre-
quency in sporadic localized neuroendocrine tumors and an up
to 56% in metastatic neuroendocrine tumors.8 Recent exon
sequencing identiﬁed mutations of ATRX/DAXX both of which
are involved in chromatin regulation, providing additional
insights into the pathogenesis of PanNETs.8
The Men1 knockout (KO) mouse mimics the phenotypes
observed in patients with PanNETs. Studies on the Men1
KO mouse show that pancreatic neuroendocrine tumors
progress though 4 different stages: normal, hyperplasia, aty-
pia and adenoma.9 In the Men1 conditional KO mouse
model, menin is lost in pancreatic islets during embryogen-
esis, and hyperplastic islets can be observed as early as
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2 months. However, frank tumors do not develop until 8 to
10 months of age. In addition, even though hyperplasia is
observed in most, if not all of the pancreatic islets, only a
small percent of hyperplastic islets ultimately develop
tumors. The long tumor latency and sporadic tumor forma-
tions in the Men1 KO mouse model indicate that deletion
of Men1 is sufﬁcient to induce hyperplasia, but that addi-
tional somatic events may be required for further tumor
progression. LOH analyses also support this notion. Loss of
heterozygosity (LOH) analysis on tumors from MEN-1
patients as well as sporadic tumors found that up to 68% of
PanNETs exhibit losses of large parts of chromosome 11q.10
Kmt2a (MLL) encodes a histone H3 lysine 4 speciﬁc
methyltransferase. It is ubiquitously expressed and plays
important roles in many mouse tissues and at different
tumor stages.11-13 Rearrangements of the human KMT2A
gene by chromosomal translocation are associated with a
variety of acute myeloid and lymphoid leukemias.14 How-
ever, the functions of KMT2A in solid tumors have not
been well characterized. Interestingly, KMT2A is physically
associated with menin in conjunction with a number of
other proteins to form a COMPASS-like complex that pro-
motes histone H3 methylation.15 The KMT2A gene is
located on chromosome segment 11q23 which also fre-
quently undergoes LOH in PanNETs. Based on these
observations, we hypothesized that Kmt2a might be
involved in tumor suppression in pancreatic islet tumors. In
this study, we aim to deﬁne the role of the TrxG protein
Kmt2a in pancreatic islet tumorigenesis using genetically
modiﬁed mouse models.
Results
Pancreatic islet speciﬁc loss of Kmt2a leads to hyperplasia
To address whether Kmt2a is required for islet development
and homeostasis of adult islets, we crossed the Kmt2af/f mouse
with a RIP-Cre transgenic mouse to generate Kmt2af/f;RIP-Cre
mice. Immunohistochemical (IHC) analysis for Kmt2a was per-
formed on 2-month old mice to assess Kmt2a protein level
changes in mouse pancreatic islets. The results were consistent
with Kmt2a RT-PCR (Fig. 1A), with Kmt2a being highly
expressed (Fig. 1B). However, the Kmt2a protein signal was
almost completely lost in Kmt2af/f;RIP-Cre pancreatic islets
upon introduction of RIP-Cre(Fig. 1B), suggesting that RIP-Cre
could efﬁciently delete the Kmt2a allele in pancreatic islets.
Islet-speciﬁc Kmt2a knockout mice were viable and did not
show a reduced lifespan compared to control mice (data not
shown). The pancreata from Kmt2af/f;RIP-Cremice and control
mice were collected at 2 months, 6 months, and 10 months and
Figure 1. Kmt2a inactivation leads to mild islet hyperplasia in mouse pancreatic islets. (A) Kmt2a expression was evaluated over time in mouse pancreatic islet cells by RT-
PCR. Men1 expression served as the control. (B) Detection of Kmt2a by immunohistochemistry in RIP-Cre, Kmt2af/f;RIP-Cre, Men1f/f;RIP-Cre and Kmt2af/f;Men1f/f;RIP-Cre pan-
creatic islets in 2-month old mice. (C) Representative H&E staining of pancreata from mice with the indicated genotypes. (Scale bar: 100mm) (D) Average pancreatic islet
size. Islet size was estimated by measuring the area of an islet using Image J. The 10 largest islets were measured in each mouse, and the average islet size was generated
from 80 islets for each genotype.
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were examined for islet morphology by histological analysis. At
the 2-month stage and 6-month stage, the morphology and size
of islets from Kmt2af/f;RIP-Cre mice were almost indistinguish-
able from those in control mice, indicating that Kmt2a is not
required for pancreatic islet development. However, at 10-
months the islets in Kmt2af/f;RIP-Cre mice were signiﬁcantly
larger than those in control mice, suggesting that Kmt2a inacti-
vation causes a hyperplastic phenotype (Figs. 1C and 1D).
Further analysis of Kmt2af/f;RIP-Cre mice at 12 months and
16 months conﬁrmed the presence of hyperplasia, but no frank
tumors were detected in Kmt2af/f;RIP-Cre mice (data not
shown). This study indicates that ablation of Kmt2a can cause
modest hyperplasia in mouse pancreatic islets even though
Kmt2a loss does not lead to pancreatic islet tumors on its own.
Ablation of Kmt2a in the Men1-deﬁcient mouse
leads to reduced survival through hyperinsulinemia
and hypoglycemia
To address whether Kmt2a inactivation has biological con-
sequences in mice with a Men1 null background, we gener-
ated Kmt2af/f;Men1f/f;RIP-Cre mice. Kmt2a IHC on islets
from Kmt2af/f;Men1f/f;RIP-Cre mice showed that the Kmt2a
signal is almost completely lost (Fig. 1B). Over time, the
median survival time for Men1f/f;RIP-Cre mice (N D 25)
was 313 days, while the median survival time for Kmt2af/f;
Men1f/f;RIP-Cre mice (N D 16)was markedly shorter at
258 days, indicating that Kmt2a loss shortens the life span
of Men1-deﬁcient mice (Fig. 2A). Similarly, within the same
littermates the median survival time for Kmt2af/f;Men1f/f;
RIP-Cre mice (N D 10) was 274 d compared to 334 d for
Men1f/f;RIP-Cre mice (N D 12) when both Kmt2af/f;Men1f/f;
RIP-Cre mice and Men1f/f;RIP-Cre mice were generated
from the same littermates (Fig. S1).
The plasma insulin levels were measured at 2 months,
4 months, 6 months, 8 months and 10 months to assess
hypoglycemia within the cohort. In Men1f/f;RIP-Cre mice
the plasma insulin levels began to gradually increase at
»4 months of age and became signiﬁcantly elevated by
6 months, whereas the plasma insulin levels in Kmt2af/f;
Men1f/f;RIP-Cre mice began to rise at 4 months and then
quickly surpassed Men1f/f;RIP-Cre mouse insulin levels
(Fig. 2B). These results suggest that the combined loss of
kmt2a and Men1 leads to an earlier onset of tumor forma-
tion as evidenced by hyperinsulinemia.
Ablation of Kmt2a promotes tumorigenesis in Men1-
deﬁcient pancreatic islets
We harvested mouse pancreata from Men1f/f;RIP-Cre and from
Kmt2af/f;Men1f/f;RIP-Cre mice and conducted histological anal-
ysis to examine pancreatic islet size. We found that the islet cell
morphology and islet size in Kmt2af/f;Men1f/f;RIP-Cre mice
were indistinguishable from that inMen1f/f;RIP-Cre mice at age
of 2 months and 4 months (Fig. 3A). However, by 6 months of
age, the islets in Kmt2af/f;Men1f/f;RIP-Cre mice were larger than
those in Men1f/f;RIP-Cre mice. When the pancreas was har-
vested from both strains at the 10-month stage, the islet tumor
size and the islet cell morphology in Kmt2af/f;Men1f/f;RIP-Cre
mice were consistently different from that in the Men1f/f;RIP-
Cre mice (Fig. 3A). The average islet tumor size was 2 times
larger in Kmt2af/f;Men1f/f;RIP-Cre mice than in Men1f/f;RIP-
Cre mice (Fig. 3B). Additionally, the size of both the nucleus
and cytoplasm were larger in the Kmt2af/f;Men1f/f;RIP-Cre
mice than that in Men1f/f;RIP-Cre mice (Fig. 3A).We also
observed that there were a greater number of tumors detected
in the Kmt2af/f;Men1f/f;RIP-Cre mice than that in Men1f/f;RIP-
Cre mice. When we deﬁned abnormal islets as being larger
than 0.5 mm with showing strong vascularization, we found 5
tumors in Kmt2af/f;Men1f/f;RIP-Cre mice on average compared
to only 1.3 tumors on average in Men1f/f;RIP-Cre mice
(Fig. 3C).In general, the tumor phenotypes in Kmt2af/f;Men1f/f;
RIP-Cre mice were more advanced than the tumors in Men1f/f;
RIP-Cre mice (Table S1). Thus, inactivation of Kmt2a in pan-
creatic islets promotes tumor progression rather than facilitat-
ing tumor initiation. We also observed that there were more
blood vessels in tumors from the Kmt2af/f;Men1f/f;RIP-Cre
mice compared toMen1f/f;RIP-Cre mice (Figs. S2A and S2B).
Kmt2a loss results in more cell proliferation in hyperplastic
islets and tumors in Kmt2af/f; Men1f/f; RIP-Cremice
We next utilized immunohistochemical analysis to investigate
whether the larger hyperplastic islets and increased number of
tumors observed in Kmt2af/f;Men1f/f;RIP-Cre mice were a con-
sequence of increased cell proliferation or reduced apoptosis.
We found that there were elevated numbers of mitotic cells in
Figure 2. Loss of Kmt2a shortens life span in Men1-deﬁcient mice. (A) Kaplan-Meier survival curves comparing Men1f/f;RIP-Cre mice (n D 24) with Kmt2af/f; Men1f/f;RIP-Cre
mice (n D 16; P < 0.0001). (B) Circulating insulin levels in mice with the indicated genotypes (paired sample t test: p D 0.03 at 6 months).
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Kmt2af/f;Men1f/f;RIP-Cre mice compared to Men1f/f;RIP-Cre
mice (Figs. 4A and 4B). A PanNET is considered to be a malig-
nant tumor if there are more than 20 mitotic cells in 10 high
power ﬁelds.16 There were approximately 20 more mitotic cells
in one Kmt2af/f;Men1f/f;RIP-Cre tumor than that in a compara-
ble the Men1f/f;RIP-Cre tumor(Fig. 4C), indicating that tumors
caused by Men1 and Kmt2a loss are more proliferative than
those caused by loss ofMen1 alone.
Next we performed IHC staining for the mitotic marker
H3S10P17in islets harvested from RIP-Cre, Men1f/f;RIP-Cre and
Kmt2af/f;Men1f/f;RIP-Cre mice. As expected, the Men1f/f;RIP-
Cre islets showed more H3S10P positive cells than RIP-Cre
control islets (Fig. 5A). However, In Kmt2af/f;Men1f/f;RIP-Cre
islets, there were many more H3S10P positive cells when com-
pared withMen1f/f;RIP-Cre islets, thus demonstrating increased
mitosis(Fig. 5A). Quantiﬁcation of H3S10P positive cells
showed that there were 8 times more mitotic cells in Kmt2af/f;
Men1f/f;RIP-Cre islets than that in Men1f/f;RIP-Cre islets
(Fig. 5C). Additionally, H3S10P staining in 10-month islets/
tumors consistently showed more H3S10P positive cells in
Kmt2af/f;Men1f/f;RIP-Cre tumors compared to that in Men1f/f;
RIP-Cre tumors (Figs. S3A and S3C).
TUNEL assays performed on islets/tumors from RIP-Cre,
Men1f/f;RIP-Cre and Kmt2af/f;Men1f/f;RIP-Cre mice revealed
that there were similar numbers of apoptotic cells in all 3 of the
tested trains (Figs. 5B and 5D). Cleaved Caspase-3 (CC3) IHC
staining was also performed in these islets; similar numbers of
CC3 positive cells were observed in the islets (Figs. S3B and
S3D). Statistical analyses did not show a signiﬁcant difference
between islets. These studies indicate that the more highly
mitotic tumor phenotypes observed in Kmt2af/f;Men1f/f; RIP-
Cre mice were more likely due to increased cell proliferation
rather than decreased apoptosis.
Discussion
Kmt2a function during islet development and islet
function in the adult stage
Kmt2a functions are not only critical for embryonic devel-
opment, but are also essential for the maintenance of
homeostasis in particular lineage/tissues such as haemato-
poietic stem cells as well as during neurogenesis in mouse
postnatal brain.13 Kmt2a is also highly expressed in mouse
pancreatic islets. Our study reveals that Kmt2a is dispens-
able for islet development as there is no detectable differ-
ence in islet numbers in Kmt2a-deﬁcient mice compared
with RIP-Cre control mice. However, Kmt2a is required for
adult islet homeostasis as the loss of Kmt2a was found to
lead to advanced hyperplasia in adult mice. Our
Figure 3. Ablation of Kmt2a accelerates Men1-defective pancreatic islet cell tumorigenesis. (A) Representative H&E staining of pancreata from mice with the indicated
genotypes. (Scale bar: 100mm) (B) Average pancreatic islet/tumor size. Islet size was estimated by measuring the islet area (tumor in Men1f/f;RIP-Cre mice and Kmt2af/f;
Men1f/f;RIP-Cre mice) using Image J. The 10 largest islets were measured in each mouse and the average islet size was generated from 100 islets for each genotype. (C)
Average tumor numbers in Men1f/f;RIP-Cre mice and Kmt2af/f;Men1f/f;RIP-Cre mice.
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investigation indicates that Kmt2a is not a neuroendocrine-
speciﬁc tumor suppressor as no tumors were observed in
Kmt2a-deﬁcient mice. Consistent with this observation, we
did not observe any survival disadvantage upon Kmt2a loss
in islets. Possible explanations include: Kmt2a function
might indeed be dispensable for islet cell differentiation
and/or Kmt2a loss might be compensated by Kmt2a family
members such as Kmt2b, Kmt2c, or Kmt2d.
Figure 4. Kmt2a loss leads to a robust increase in mitotic cells. Mitotic cells were observed from Kmt2af/f;Men1f/f;RIP-Cre but not in Men1f/f;RIP-Cre islets in (A) (lower
magniﬁcation, Scale bar: 100 mm) and (B) (higher magniﬁcation, Scale bar: 100mm). Arrow indicates cells undergoing mitosis.(C): Quantiﬁcation of mitotic cells from
hyperplastic islets/tumors harvested from mice with the indicated genotypes at an age of 10 months.
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Kmt2a cooperates withMEN1 to prevent tumor formation
Men1-deﬁcent islets quickly become hyperplastic at 2 to
4 months of age. However, it takes 6 to 8 months for the hyper-
plastic islet to develop detectable tumors. Thus, other genetic
or epigenetic alterations must likely occur to facilitate tumor
progression. During human MEN-1 syndrome, MEN1 is
mutated at the germline level and the second allele is frequently
lost through LOH, which often involves a broad region of 11q.
As KMT2A is located in 11q23 within 10 Mb of the MEN1
locus, KMT2A is frequently lost in tumors from patients with
MEN-1 syndrome. Although Kmt2a loss in mice by itself does
not lead to tumor formation, Kmt2a inactivation accelerates
islet tumor progression in the Men1-deﬁcient mouse. This
study indicates that Men1 is a driver and initiator of islet
tumors whereas Kmt2a loss can facilitate tumor progression.
Kmt2a might be involved in islet tumorigenesis in both a
menin-dependent and a menin-independent manner. As a
menin-associated protein, Kmt2a might partially compensate
for menin dysfunction and maintain key downstream targets.
Whereas when Kmt2a is inactivated, menin might counteract
the effect caused by Kmt2a loss. On the other hand, although
menin is a component of the COMPASS-like complex that pro-
motes histone H3 methylation under certain circumstance,
Kmt2a might be critical for certain important genes in pancre-
atic islets which are independent of menin. Our preliminary
ChIP-seq and RNA-Seq data (unpublished) show that the
expression of several islet-speciﬁc transcription factors is posi-
tively regulated by Kmt2a enzymatic activity, but not menin
activity. Further experiments should be conducted to address
these remaining questions.
Advanced mouse models for molecular pathology studies
and preclinical studies
Currently two targeted therapies for pancreatic neuroendocrine
tumors have been approved by the FDA,6,7 indicating that tar-
geted therapies can be developed for the treatment of pancre-
atic neuroendocrine cancer. However, current targeted
therapies only prolong progression-free survival for approxi-
mately 6 months,6,7 providing only a modest beneﬁt to patients
with this type of cancer. Additionally the response rates are
very low when patients with advanced PanNETs were treated
with the tyrosine kinase inhibitor sunitinib and the mTOR
inhibitor everolimus.6,7 Targeted therapeutic approaches which
combine the effect of both mTOR inhibition and angiogenesis
inhibition have shown substantial anti-cancer activity,18 and
new potential approaches have been proposed.2 In principle,
better mouse models will help to develop improved targeted
therapies. The Kmt2af/f;Men1f/f;RIP-Cre mouse has more
advanced tumor phenotypes than other models, so this mouse
model may be more suitable as a preclinical mouse model for
testing new targeted therapies for pancreatic neuroendocrine
Figure 5. More cell proliferation rather than less apoptosis is observed in Kmt2af/f;Men1f/f;RIP-Cre islets in 6-month old mice. (A) Histone H3 serine 10 phosphorylation was
evaluated in pancreatic islet cells at the age of 6 months with the indicated genotypes by immunohistochemistry (IHC). The dark brown color indicates positivity for Anti-
Histone H3(phospho S10). (B) Apoptosis was measured via TUNEL assay. The dark brown color indicates apoptosis positive cells. (C) Quantiﬁcation of proliferating cells
from hyperplastic islets harvested from mice with the indicated genotypes at an age of 6 months.  , P< 0.01 (D) Quantiﬁcation of apoptotic cells from hyperplastic islets
harvested from mice with the indicated genotypes at an age of 6 months.
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tumors. In addition, menin is physically associated with Kmt2a,
which is critical in leukemia mediated by Kmt2a fusion pro-
teins. Several inhibitors that speciﬁcally disrupted the menin-
Kmt2a interaction have been developed and pharmacologic
inhibition has shown a very promising response.19-21 Disrup-
tion of Kmt2a does not lead to phenotypes in early stage of
islets whereas Men1 deletion causes a hyperplastic phenotype,
suggesting that menin has Kmt2a-independent roles in the
maintenance of homeostasis in mouse pancreatic islets, which
is consistent with a recent study in the haematopoietic sys-
tem.22 This observation may alleviate some concern regarding
the potential strong side effect on pancreatic function when
applying these MI-2 and related inhibitors in patients with
Kmt2a-associated leukemia.
Materials and methods
Generation of mouse strains
The creation and genotyping of RIP-Cre mice, Men1ﬂf;RIP-Cre
mice has been described previously.23 Kmt2aﬂf mice were crossed
with RIP-Cre mice24 to obtain Kmt2af/C;RIP-Cre mice. Kmt2af/C;
RIP-Cre mice were crossed with Kmt2af/Cmice to generate
Kmt2af/f;RIP-Cre mice. Kmt2af/f mice were crossed with Men1ﬂf;
RIP-Cre mice to obtain Kmt2af/C;Men1ﬂC;RIP-Cre, Kmt2af/C;
Men1ﬂC;RIP-Cre were then crossed with Kmt2af/C;Men1ﬂC mice
to obtain Kmt2af/f;Men1ﬂf;RIP-Cre mice. Mice were maintained
on a mixed 129s6, FVB/N, and C57BL/6 background. All mice
were maintained in the research animal facility of the Dana–
Farber Cancer Institute and Hefei Institutes of Physical Science
Laboratory Animal Center, Chinese Academy of Sciences. All pro-
cedures were performed in accordance with the National Research
Council Guide for the Care and Use of laboratory Animals and
were approved by the Institutional Animal Care and Use Com-
mittee of both the Dana-Farber Cancer Institute and Hefei Insti-
tutes of Physical Science, Chinese Academy of Sciences.
Isolation of mouse pancreatic islets
Pancreatic islets were isolated as previously described.23
Circulating insulin measurement
Blood was collected via the submandibular vein method after
the mice were fasted for 16h. Plasma was prepared by spinning
a tube of fresh blood containing an anticoagulant. The circulat-
ing insulin level was measured using an ultra sensitive Mouse
ELISA kit (Crystal Chemical, Downers Grove, IL, USA) accord-
ing to the manufacturer’s instructions.
Histological and immunohistochemical analysis
of pancreatic tissues
Pancreata were collected from mice at indicated time points
and ﬁxed in 4% paraformaldehyde for 2 hours followed by
dehydration and parafﬁn embedding. Histopathological analy-
sis was carried out on 5-micrometer sections stained with
hematoxylin and eosin. Islet morphology and tumors were
examined in at least 3 cut sections for each pancreas after
staining with hematoxylin and eosin. Appropriate positive and
negative controls were run on matched sections for all applied
antibodies. Immunohistochemical staining was performed on
serial sections using antibodies against Kmt2a (GeneTax,
GTX17959, 1:400), Anti-Histone H3(Phospho S10) (Abcam,
Ab14955, 1:180), and CC3 (Thermo, PA1-24473. 1:100). Sec-
tions were counterstained in Meyer’s hematoxylin, mounted
and photographed using an Olympus microscope.
RNA isolation and RT-qPCR
Total RNA was extracted using the RNeasy kit (Qiagen) from 100
to 300 mouse pancreatic islets puriﬁed from 2 mice with different
genotypes according to the manufacturer’s instructions. For RT-
PCR, DNase I (Qiagen)-treated RNA samples were reverse tran-
scribed using oligo-dT and SuperScript III (Invitrogen), with ﬁrst
strand cDNA for PCR created using SYBR green PCRmix (Qiagen,
Valencia, California, United States) in an Applied Biosystems 7300
Real Time-PCR system (Foster City, California, United States).
PCR primer pairs were designed to amplify 150- to 200-bp frag-
ments from select genomic regions. Quantiﬁcation of mRNA
expression in each sample was performed by normalizing values to
the expression values for Gapdh. Primer sequences for Kmt2a
are 50-CATTCGGCAAATGGAGCGAG-30(forward) and
50-TAGAGGAGGCTGCTCAGTGT-30 (reverse); primer sequen-
ces forMen1 are 50-GATGGACATCTCTGAGACCCA-30(for-
ward) and 50-CCAGTCCCTCTTCAGCTTCA-30(reverse); primer
sequences for Gapdh are 50-TCAATGAAGGGGTCGTTGAT-30
(forward) and 50-CGTCCCGTAGACAAAATGGT-30 (reverse).
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